semaglutide first‑line obesity
Semaglutide vs Tirzepatide - Why the First Wins
Semaglutide is the preferred first-line option for obesity because it is endorsed by the 2023 ACP guidelines and consistently delivers 15-17% weight loss over 68 weeks, while offering a more tolerable safety profile. Clinicians looking for a reliable pharmacologic pathway can rely on this GLP-1 receptor agonist to meet guideline